Lilly Endowment Inc, an insider at Eli Lilly and Co (LLY), sold 93,769,190 shares on November 4, 2025, at a price of $944.68 per share, totaling approximately $88.58 billion. Following this transaction, Lilly Endowment Inc retains 93,769,190 shares in the company.
Eli Lilly, headquartered in Indianapolis, Indiana, engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company has a market capitalization of $886.2 billion and a P/E ratio of 48.13. Its diverse portfolio includes products for cardiometabolic health, oncology, immunology, and neuroscience.
This insider sale provides a glimpse into the financial maneuvers of company executives. While large transactions may attract investor attention, such sales can occur for a variety of personal reasons, including diversification or tax planning. Investors are advised to consider broader patterns of insider activity rather than isolated transactions when assessing market signals.
Eli Lilly is expected to report its next earnings on April 28, 2026, with an estimated EPS of $7.07 and revenue of $17.2 billion, followed by another report on August 4, 2026, with an estimated EPS of $7.70 and revenue of $17.9 billion.